Prot #PCI-32765MCL4001: An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date8/27/139/30/14

Funding

  • Quintiles, Inc. (Prot #PCI-32765MCL4001)
  • Janssen Research & Development, LLC (Prot #PCI-32765MCL4001)